Literature DB >> 33546081

Toxic epidermal necrolysis in a patient on atorvastatin therapy expressing human leukocyte antigen alleles: A case report.

Meina Lv1,2, Shaojun Jiang1,2, Jinglan Fu1,2, Yuxin Liu1,3, Siheng Lian1,2, Jinhua Zhang1,2.   

Abstract

RATIONALE: Toxic epidermal necrolysis (TEN) is a rare, severe mucosal response of the skin associated with a high mortality rate. TEN is most commonly caused by drugs, and is characterized by extensive skin epidermal exfoliation. PATIENT CONCERNS: A 68-year-old woman presented with a rash that had persisted for four days. The patient who had undergone a mitral valve replacement 1 month prior and was taking atorvastatin at the time of admission. DIAGNOSES: The patient exhibited more than 30% exfoliation surfaces and the severe drug eruption was considered to be TEN. According to human leukocyte antigen (HLA) allele detection and ALDEN score, HLA alleles which found in this case report may be an cause of TEN induced by atorvastatin.
INTERVENTIONS: All drugs used prior to admission were discontinued and the patient was given antiallergic drugs. OUTCOMES: After 3 weeks following Antiallergic treatment, the rash on patient's calf had subsided, the edema was relieved, and the patient was no longer experiencing pain. After 60 days following discharge, the patient's skin has regrown. LESSONS: This is the first report describing the induction of TEN by atorvastatin in a HLA alleles carrier. For HLA alleles carrier, atorvastatin may need to be used with caution to avoid TEN. Future systematic research is also required to confirm this finding and avoid similar serious skin adverse reactions.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33546081      PMCID: PMC7837978          DOI: 10.1097/MD.0000000000024392

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  14 in total

1.  Toxic epidermal necrolysis from atorvastatin.

Authors:  C M Pfeiffer; S Kazenoff; H D Rothberg
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

2.  UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016.

Authors:  D Creamer; S A Walsh; P Dziewulski; L S Exton; H Y Lee; J K G Dart; J Setterfield; C B Bunker; M R Ardern-Jones; K M T Watson; G A E Wong; M Philippidou; A Vercueil; R V Martin; G Williams; M Shah; D Brown; P Williams; M F Mohd Mustapa; C H Smith
Journal:  J Plast Reconstr Aesthet Surg       Date:  2016-06       Impact factor: 2.740

3.  ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.

Authors:  B Sassolas; C Haddad; M Mockenhaupt; A Dunant; Y Liss; K Bork; U F Haustein; D Vieluf; J C Roujeau; H Le Louet
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

4.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology-Thirty Years of Progress but Still Much to Be Done.

Authors:  Robert S Stern; Sherrie J Divito
Journal:  J Invest Dermatol       Date:  2017-05       Impact factor: 8.551

5.  Distribution of HLA-A, -B, -Cw, and -DRB1 alleles and haplotypes in an isolated Han population in Southwest China.

Authors:  Y Yao; L Shi; L Shi; M Matsushita; L Yu; K Lin; Y Tao; X Huang; W Yi; T Oka; K Tokunaga; J Chu
Journal:  Tissue Antigens       Date:  2009-06

Review 6.  Statins: novel additions to the dermatologic arsenal?

Authors:  M R Namazi
Journal:  Exp Dermatol       Date:  2004-06       Impact factor: 3.960

7.  HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome.

Authors:  Chih-Wen Ou Yang; Shuen-Iu Hung; Chiun-Gung Juo; Ya-Ping Lin; Wu-Hsiang Fang; I-Hsuan Lu; Shui-Tein Chen; Yuan-Tsong Chen
Journal:  J Allergy Clin Immunol       Date:  2007-08-13       Impact factor: 10.793

Review 8.  HLA Association with Drug-Induced Adverse Reactions.

Authors:  Wen-Lang Fan; Meng-Shin Shiao; Rosaline Chung-Yee Hui; Shih-Chi Su; Chuang-Wei Wang; Ya-Ching Chang; Wen-Hung Chung
Journal:  J Immunol Res       Date:  2017-11-23       Impact factor: 4.818

9.  The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China.

Authors:  Shang-Chen Yang; Sindy Hu; Sheng-Zheng Zhang; Jin-Wen Huang; Jing Zhang; Chao Ji; Bo Cheng
Journal:  J Immunol Res       Date:  2018-02-11       Impact factor: 4.818

10.  A fatal case of cutaneous adverse drug-induced toxic epidermal necrolysis associated with severe rhabdomyolysis.

Authors:  Sheik Oaleed Noordally; Schoeb Sohawon; Julien Vanderhulst; Ruth Duttmann; Francis Corazza; Jacques Devriendt
Journal:  Ann Saudi Med       Date:  2012 May-Jun       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.